Quantcast
Home / News / Suit against maker of generic Reglan preempted

Suit against maker of generic Reglan preempted

A “failure to communicate” claim against the maker of generic Reglan was completely preempted by federal law regulating the pharmaceutical industry, the 11th U.S. Circuit Court of Appeals has ruled in affirming judgment.
Scroll To Top